RTTNews | Jun 8, 2021 11:00AM EDT

11:00 Tuesday, June 8, 2021 (RTTNews.com) - Shares of German biopharmaceutical company CureVac N.V. (CVAC) are down 13 percent on Tuesday's trading on reports that the European Medicines Agency will not take a decision on the approval of the company's COVID-19 vaccine before August.

Earlier, the company had said that a late-stage trial including 40,000 volunteers in Europe and Latin America had reached a first interim analysis at 59 COVID-19 cases, but more data would be needed for statistically reliable efficacy numbers.

The stock is currently trading at $108.30, down $16.70 or 13% on the NASDAQ.

CVAC has traded between $36.15 and $151.80 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3200851/stock-alert-curevac-slips-13.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved